Impact of BRCA1 and BRCA2 Mutations on Ovarian Reserve and Fertility Preservation Outcomes in Young Women with Breast Cancer

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2019 Dec 25

PMID 31872386

Citations 26

Authors

Eleonora Porcu

Giulia Maria Cillo

Linda Cipriani

Federica Sacilotto

Leonardo Notarangelo

Giuseppe Damiano

Maria Dirodi

Ilaria Roncarati

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes.

Methods: Prospective study: 67 breast cancer patients between 18 and 40 years old, undergoing a fertility preservation by means of oocyte storage were considered. Inclusions criteria for the study were age between 18 and 40 years old, BMI between 18 and 28, breast cancer neoplasm stage I and II according to American Joint Committee on Cancer classification (2017) and no metastasis.

Exclusion Criteria: age over 40 years old, BMI < 18 and > 28, breast cancer neoplasm stage III and IV and do not performed the BRCA test. A total of 21 patients had not performed the test and were excluded. Patients were divided into four groups: Group A was composed by 11 breast cancer patients with BRCA 1 mutations, Group B was composed by 11 breast cancer patients with BRCA 2 mutations, Group C was composed by 24 women with breast cancer without BRCA mutations, and Group D (control) was composed by 181 normal women.

Results: Group A showed significant lower AMH levels compared to Group C and D (1.2 ± 1.1 vs 4.5 ± 4.1 p < 0.05 and 1.2 ± 1.1 vs 3.8 ± 2.5 p < 0.05). BRCA1 mutated patients showed a significant lower rate of mature oocytes (MII) compared to Group C (3.1 ± 2.3 vs 7.2 ± 4.4 p < 0,05) and Group D (3.1 ± 2.3 vs 7.3 ± 3.4; p < 0,05). Breast cancer patients needed a higher dose of gonadotropins compared to controls (Group A 2206 ± 1392 Group B2047.5 ± 829.9 Group C 2106 ± 1336 Group D 1597 ± 709 p < 0,05). No significant differences were found among the groups considering basal FSH levels, duration of stimulation, number of developed follicles, and number of total retrieved oocytes. Regarding BRCA2 mutation, no effect on fertility was shown in this study.

Conclusions: The study showed that BRCA1 patients had a higher risk of premature ovarian insufficiency (POI) confirmed by a diminished ovarian reserve and a lower number of mature oocytes suitable for cryopreservation.

Citing Articles

Anti-Müllerian hormone: biology and role in endocrinology and cancers.

Gowkielewicz M, Lipka A, Zdanowski W, Wasniewski T, Majewska M, Carlberg C Front Endocrinol (Lausanne). 2024; 15:1468364.

PMID: 39351532 PMC: 11439669. DOI: 10.3389/fendo.2024.1468364.

Knowledge and intentions to use fertility preservation among urban Chinese cancer patients: A study from Hong Kong.

Chan L, Cochon K, Li T, Chung J, Kim J PLoS One. 2024; 19(9):e0307715.

PMID: 39259733 PMC: 11389933. DOI: 10.1371/journal.pone.0307715.

Reproductive genetics and health.

Wyrwoll M, Steingrover J Med Genet. 2024; 36(3):179-188.

PMID: 39257928 PMC: 11382347. DOI: 10.1515/medgen-2024-2036.

Molecular Factors Predicting Ovarian Chemotoxicity in Fertile Women: A Systematic Review.

Raimondo D, Raffone A, Neola D, Genovese F, Travaglino A, Aguzzi A Cancers (Basel). 2024; 16(16).

PMID: 39199566 PMC: 11352339. DOI: 10.3390/cancers16162793.

Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review.

Dellino M, Damato A, Battista G, Cormio G, Vimercati A, Loizzi V Open Med (Wars). 2024; 19(1):20249999.

PMID: 39176249 PMC: 11340857. DOI: 10.1515/med-2024-9999.

References

Gunnala V, Fields J, Irani M, DAngelo D, Xu K, Schattman G . BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2018; 111(2):363-371. DOI: 10.1016/j.fertnstert.2018.10.014. View

Welt C . Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2007; 68(4):499-509. DOI: 10.1111/j.1365-2265.2007.03073.x. View

Johnson L, Sammel M, Domchek S, Schanne A, Prewitt M, Gracia C . Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017; 107(5):1256-1265.e6. PMC: 5531590. DOI: 10.1016/j.fertnstert.2017.03.018. View

Wang E, Pisarska M, Bresee C, Chen Y, Lester J, Afshar Y . BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014; 102(6):1723-8. PMC: 4372188. DOI: 10.1016/j.fertnstert.2014.08.014. View

Lin W, Titus S, Moy F, Ginsburg E, Oktay K . Ovarian Aging in Women With BRCA Germline Mutations. J Clin Endocrinol Metab. 2017; 102(10):3839-3847. PMC: 5630253. DOI: 10.1210/jc.2017-00765. View

Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D . BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015; 104(5):1162-7. DOI: 10.1016/j.fertnstert.2015.07.1162. View

Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R . Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2011; 97(1):125-33. DOI: 10.1016/j.fertnstert.2011.10.014. View

Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S . Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes. 2008; 15(6):529-35. DOI: 10.1097/MED.0b013e3283199129. View

Loren A, Mangu P, Beck L, Brennan L, Magdalinski A, Partridge A . Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(19):2500-10. PMC: 5321083. DOI: 10.1200/JCO.2013.49.2678. View

10.

Porcu E, Venturoli S, Damiano G, Ciotti P, Notarangelo L, Paradisi R . Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online. 2008; 17(2):265-7. DOI: 10.1016/s1472-6483(10)60204-0. View

11.

Peccatori F, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F . Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?. Hum Reprod. 2017; 33(2):181-187. DOI: 10.1093/humrep/dex356. View

12.

Son K, Lee D, Choi D . Association of Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients. Front Endocrinol (Lausanne). 2019; 10:235. PMC: 6470199. DOI: 10.3389/fendo.2019.00235. View

13.

Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C . Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. J Adolesc Young Adult Oncol. 2016; 5(4):337-343. PMC: 5144867. DOI: 10.1089/jayao.2016.0009. View

14.

Tucker E, Grover S, Bachelot A, Touraine P, Sinclair A . Premature Ovarian Insufficiency: New Perspectives on Genetic Cause and Phenotypic Spectrum. Endocr Rev. 2016; 37(6):609-635. DOI: 10.1210/er.2016-1047. View

15.

Agarwal A, Said T . Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2005; 9(6):673-9. DOI: 10.1016/s1472-6483(10)61779-8. View

16.

Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K . Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013; 5(172):172ra21. PMC: 5130338. DOI: 10.1126/scitranslmed.3004925. View

17.

Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C . Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013; 31(31):3914-9. PMC: 3805929. DOI: 10.1200/JCO.2012.47.7893. View

18.

Goodwin P, Ennis M, Pritchard K, Trudeau M, Hood N . Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17(8):2365-70. DOI: 10.1200/JCO.1999.17.8.2365. View

19.

Lekovich J, Lobel A, Stewart J, Pereira N, Kligman I, Rosenwaks Z . Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet. 2016; 33(5):657-662. PMC: 4870447. DOI: 10.1007/s10815-016-0689-1. View

20.

Savage K, Matchett K, Barros E, Cooper K, Irwin G, Gorski J . BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res. 2014; 74(10):2773-2784. PMC: 4024319. DOI: 10.1158/0008-5472.CAN-13-2611. View